4570 — Immuno-Biological Laboratories Co Cashflow Statement
0.000.00%
Last trade - 00:00- ¥4bn
- ¥4bn
- ¥817m
- 64
- 31
- 51
- 47
Annual cashflow statement for Immuno-Biological Laboratories Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -659 | -311 | -250 | -281 | 125 |
| Depreciation | |||||
| Non-Cash Items | 78 | 86.7 | 134 | 349 | -7.84 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -28.1 | 29.8 | 22.5 | 11 | 14.6 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Accounts Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -609 | -194 | -93.2 | 79.7 | 134 |
| Capital Expenditures | — | -13.5 | — | — | -18.7 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 10.8 | -3.77 | -156 | 30 | -5.84 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 10.8 | -17.2 | -156 | 30 | -24.5 |
| Financing Cash Flow Items | -278 | -200 | — | -0.001 | 0 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 81.2 | -216 | 144 | 0.991 | 0.992 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -517 | -422 | -103 | 113 | 113 |